All In Biotech

Drug Trial Radar · NCT06475989

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

264

Planned (sponsor's estimate)

Start

Dec 27, 2024

Primary completion

Sep 30, 2030

Study completion Sep 30, 2030

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
First posted
Jun 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth of tumor cells and blood vessels the tumor needs to survive. Dabrafenib is an enzyme inhibitor that binds to and inhibits the activity of a protein called B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. Trametinib is also an enzyme inhibitor. It binds to and inhibits the activity of proteins called MEK 1 and 2, which play a key role in activating pathways that regulate cell growth. This may inhibit the growth of tumor cells mediated by these pathways. The usual approach for patients with thyroid cancer is targeted therapy with dabrafenib and trametinib. This trial may help researchers decide which treatment option (cabozantinib alone or dabrafenib in combination with trametinib) is safer and/or more effective in treating patients with refractory BRAF V600E-mutated differentiated thyroid cancer.

Conditions

  • Refractory Differentiated Thyroid Gland Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • CabozantinibDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT scan

  • DabrafenibDrug

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Questionnaire AdministrationOther

    Ancillary study

  • TrametinibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: From randomization to radiographic progression of disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or death from any cause, up to 5 years

Locations

307 sites in 1 country. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Recruiting

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska · Suspended

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Recruiting

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Recruiting

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Recruiting

  • Katmai Oncology Group

    Anchorage, Alaska · Recruiting

  • Providence Alaska Medical Center

    Anchorage, Alaska · Recruiting

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska · Recruiting

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Recruiting

  • CARTI Cancer Center

    Little Rock, Arkansas · Recruiting

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • Providence Queen of The Valley

    Napa, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Recruiting

  • Providence Medical Foundation - Santa Rosa

    Santa Rosa, California · Recruiting

  • Providence Santa Rosa Memorial Hospital

    Santa Rosa, California · Recruiting

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • UCHealth Highlands Ranch Hospital

    Highlands Ranch, Colorado · Recruiting

  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center-Fairfield

    Fairfield, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center at Glastonbury

    Glastonbury, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center at Greenwich

    Greenwich, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center - Guilford

    Guilford, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut · Recruiting

  • Smilow Cancer Center/Yale-New Haven Hospital

    New Haven, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Yale-New Haven Hospital North Haven Medical Center

    North Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center at Long Ridge

    Stamford, Connecticut · Recruiting

  • Smilow Cancer Hospital-Torrington Care Center

    Torrington, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut · Recruiting

  • Smilow Cancer Hospital-Waterbury Care Center

    Waterbury, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center - Waterford

    Waterford, Connecticut · Recruiting

  • Holy Cross Hospital

    Fort Lauderdale, Florida · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Active not recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

Showing 40 of 307 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.